TABLE 1.
Patient characteristics at baseline.
| Characteristics | Total 153 patients | |
|---|---|---|
| Age, mean ± SD (range), years | 48.6 ± 12.8 (22–80) | (n = 153) |
| Overweight (BMI >25 kg/m2), n (%) | 75 (67) | (n = 112) |
| Testis volume | (n = 75) | |
| Left testis, median (IQR) | 18.0 (15.0–20.0) | |
| Right testis, median (IQR) | 18.0 (15.0–18.0) | |
| Medical history | (n = 153) | |
| Klinefelter, n (%) | 1 (1) | |
| Orchiectomy, n (%) | 41 (27) | |
| Orchidopexy, n (%) | 5 (3) | |
| Vasectomy, n (%) | 17 (11) | |
| Vasovasostomy, n (%) | 3 (2) | |
| Diabetes mellitus, n (%) | 15 (10) | |
| Testicular tumour, n (%) | 38 (23) | |
| Other malignancies*, n (%) | 16 (10) | |
| Pituitary adenoma, n (%) | 2 (1) | |
| HIV, n (%) | 3 (2) | |
| Myocardial or brain infarction, n (%) | 16 (10) | |
| Hypertension, n (%) | 19 (12) | |
| Thrombosis or lung embolus, n (%) | 5 (3) | |
| Polycythaemia, n (%) | 2 (1) | |
| Dosage of CC therapy at start | (n = 153) | |
| 25 mg/2 day | 132 (86) | |
| 25 mg/day | 9 (6) | |
| 50 mg/2 day | 6 (4) | |
| 50 mg/day | 3 (2) | |
| 25 mg/3 day | 1 (1) | |
| Switching between 25 or 50 mg/day | 1 (1) | |
Abbreviations: BMI, body mass index; IQR, interquartile range; n, number of patients; SD, standard deviation.
*
Prostate carcinoma, renal cell carcinoma, lymphoma, Kaposi sarcoma, colon carcinoma, rectum carcinoma.